Craig-Hallum Reiterates Buy Rating on Fractyl Health, Inc.

Craig-Hallum reiterated its buy rating on Fractyl Health, Inc. (NasdaqGM: GUTS) on July 1, 2026, maintaining a price target of $4. Analyst Chase Knickerbocker reaffirmed the firm's positive outlook on the biotechnology company.

Other Institutional Activity in Fractyl Health

Several institutional investors have been active in Fractyl Health recently. Nantahala Capital Management increased its holdings by 2,518,079 shares, bringing its total to over 13.3 million shares valued at about $6.1 million, marking a 23.2% increase. 683 Capital Management also boosted its position by 679,615 shares to a total of approximately 6.7 million shares worth around $3.1 million, reflecting an 11.2% increase. Pale Fire Capital SE significantly grew its stake by 2,711,103 shares, ending with about 5.9 million shares valued at $2.7 million, an 84.5% rise. Vanguard Capital Management opened a new position with over 5.5 million shares valued at about $2.5 million.

Fractyl Health, Inc. Stock Up 21.2%

Shares of Fractyl Health, Inc. traded near $0.80 on Wednesday. The company has a market cap of approximately $126 million. Its forward P/E ratio is not meaningful as the company is not currently profitable. The stock has a beta of 2.34, indicating higher volatility compared to the market. Over the past 52 weeks, the stock has traded between $0.38 and $2.44. The 50-day moving average is $0.76, while the 200-day moving average is $1.09. Fractyl has a robust current ratio of 4.28, indicating strong liquidity, though its debt-to-equity ratio stands at a high 284.5.

Insider Buying and Selling at Fractyl Health, Inc.

There has been notable insider buying at Fractyl Health recently. On June 12, 2026, Ajay Royan acquired 23,000 shares at an average price of $0.85. Earlier, on June 10, multiple insiders, including Kelly Ann Barnes and William Bradley, bought shares at unspecified prices. William Bradley also purchased 68,493 shares at $0.73 each on the same day.

Analysts Set New Price Targets

On July 1, 2026, Craig-Hallum reiterated its buy rating on Fractyl Health, Inc. with a price target of $4. Previously, on June 4, 2026, HC Wainwright & Co. also reiterated a buy rating with a higher target of $8. The consensus among analysts is a buy rating, with a mean price target of $5.24 based on five analyst opinions.

About Fractyl Health, Inc.

Fractyl Health, Inc. is a biotechnology company focused on developing treatments for type 2 diabetes and obesity. Headquartered in Burlington, Massachusetts, and led by CEO Dr. Harith Rajagopalan, the company employs approximately 100 people. It is known for its Revita DMR System, an outpatient procedure aimed at modifying duodenal dysfunction, and Rejuva, a gene therapy platform for long-term remission of metabolic diseases.

Bottom Line

Craig-Hallum's reiterated buy rating highlights continued confidence in Fractyl Health's potential. The company's focus on novel treatments for diabetes and obesity makes it a key player in the biotechnology sector. Investors should note that analyst ratings are based on backward-looking data and may not reflect current market conditions.